The drug Femara or Letrozole is prescribed for:
Early stages of hormone-receptor breast cancer in postmenopausal women as adjuvant therapy.
Early stages of breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen as extended adjuvant therapy.
Common hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy).
Common forms of breast cancer in postmenopausal women (natural or artificially induced) who received prior antiestrogen therapy.
Active ingredient: letrozole 2.5 mg
Prescription medicine.